NantKwest, Inc. (NK): Price and Financial Metrics


NantKwest, Inc. (NK)

Today's Latest Price: $7.14 USD

0.04 (-0.56%)

Updated Sep 30 12:20pm

Add NK to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 376 in Biotech

See all "A" rated Strong Buy stocks

NK Stock Summary

  • NantKwest Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 8.61% of US listed stocks.
  • NK's price/sales ratio is 18,028.56; that's higher than the P/S ratio of 99.89% of US stocks.
  • In terms of volatility of its share price, NK is more volatile than 90.85% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to NantKwest Inc are TRVN, CYAD, TGTX, PSTI, and WKHS.
  • Visit NK's SEC page to see the company's official filings. To visit the company's web site, go to www.nantkwest.com.
NK Daily Price Range
NK 52-Week Price Range

NK Stock Price Chart Technical Analysis Charts


NK Price/Volume Stats

Current price $7.14 52-week high $15.70
Prev. close $7.18 52-week low $1.05
Day low $6.90 Volume 308,828
Day high $7.22 Avg. volume 1,885,683
50-day MA $8.98 Dividend yield N/A
200-day MA $6.72 Market Cap 770.91M

NantKwest, Inc. (NK) Company Bio


NantKwest is a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. The company was founded in 2002 and is based in Cardiff-by-the-Sea, California.


NK Latest News Stream


Event/Time News Detail
Loading, please wait...

NK Latest Social Stream


Loading social stream, please wait...

View Full NK Social Stream

Latest NK News From Around the Web

Below are the latest news stories about NantKwest Inc that investors may wish to consider to help them evaluate NK as an investment opportunity.

NantKwest to Present at the 7th Annual Jefferies Cell Therapy Summit

EL SEGUNDO, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that Patrick Soon-Shiong, M.D., Chairman and CEO, will present at the virtual Jefferies Cell Therapy Summit on Tuesday, October 6, 2020 at 12:50 PM ET. The conference presentation will be available on the NantKwest website, NantKwest.com. An archived replay will be available on the website for approximately 30 days. About NantKwest NantKwest (NASDA

Business Wire | September 21, 2020

NantKwest's NK-92 bioanalytical testing line licensed to Fresenius Kabi SwissBioSim

NantKwest's ([[NK]] +2.0%) affiliate and exclusively-licensed distributor of its proprietary off-the-shelf NK-92® natural killer cells, Brink Biologics, has licensed its natural killer-based bioanalytical testing solution, to Fresenius Kabi SwissBioSim.Brink Biologics offers NK-92 based cell lines as part of its Neukopanel portfolio for laboratory based bioanalytical testing....

Seeking Alpha | September 10, 2020

NantKwest and ImmunityBio Sign Collaboration Agreement for Joint Development, Manufacturing, Marketing, and Commercialization of COVID-19 Vaccine and Related Therapeutics

EL SEGUNDO, Calif. & CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately held immunotherapy company, today announced the signing of a definitive agreement to jointly develop, manufacture, market, and commercialize therapeutics and vaccines for combating the COVID-19 pandemic. Under the terms of the definitive agreement, the two companies agree to share equally the costs incurred after

Business Wire | August 24, 2020

NantKwest in Pact with Generate Life’s CBR on potential COVID-19 treatment

Cord Blood Registry ((CBR)) by Generate Life Sciences and NantKwest ([[NK]] +6.7%) announces collaboration for development of COVID-19 treatment leveraging newborn stem cells.CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cellsPatient trials expected to begin in the fall, and both companies anticipate an FDA-approved treatment to be in the market for...

Seeking Alpha | August 10, 2020

Cord Blood Registry (CBR®) By Generate Life Sciences Partners With NantKwest To Develop COVID-19 Treatment

LOS ANGELES, and EL SEGUNDO, Calif., Aug. 10, 2020 /PRNewswire/ -- CBR® by Generate Life Sciences, the world's largest private newborn stem cell bank, and NantKwest (Nasdaq: NK), a clinical-stage, natural killer cell-based immunotherapy company, today announced a collaboration to develop…

PR Newswire | August 10, 2020

Read More 'NK' Stories Here

NK Price Returns

1-mo -2.19%
3-mo -40.45%
6-mo 174.62%
1-year 515.52%
3-year 30.29%
5-year -41.62%
YTD 88.39%
2019 226.72%
2018 -74.16%
2017 -21.50%
2016 -66.99%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7277 seconds.